An endogenous serine/threonine protein phosphatase inhibitor, G-substrate, reduces vulnerability in models of Parkinson's disease.
about
Functional enhancement and protection of dopaminergic terminals by RAB3B overexpressionNitrated alpha-synuclein induces the loss of dopaminergic neurons in the substantia nigra of rats.The transcription factor orthodenticle homeobox 2 influences axonal projections and vulnerability of midbrain dopaminergic neurons.Stem cell transplantation in neurological diseases: improving effectiveness in animal modelsThe Toll-like receptor-3 agonist polyinosinic:polycytidylic acid triggers nigrostriatal dopaminergic degeneration.RNA Isolation from Cell Specific Subpopulations Using Laser-capture Microdissection Combined with Rapid Immunolabeling.Low Levels of Prohibitin in Substantia Nigra Makes Dopaminergic Neurons Vulnerable in Parkinson's Disease.Molecular heterogeneity of midbrain dopaminergic neurons--Moving toward single cell resolution.Unregulated mitochondrial GSK3beta activity results in NADH: ubiquinone oxidoreductase deficiency.Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy.Nitric oxide signaling in brain function, dysfunction, and dementia.Molecular determinants of selective dopaminergic vulnerability in Parkinson's disease: an update.Akt as a victim, villain and potential hero in Parkinson's disease pathophysiology and treatment.Neuroprotective Effects of Intranasal IGF-1 against Neonatal Lipopolysaccharide-Induced Neurobehavioral Deficits and Neuronal Inflammation in the Substantia Nigra and Locus Coeruleus of Juvenile Rats.Neuroprotection by urate on 6-OHDA-lesioned rat model of Parkinson's disease: linking to Akt/GSK3β signaling pathway.
P2860
Q22001521-748AC7EC-7E59-4933-9CAF-A4D4A7451DA1Q33553317-73557F48-5DD8-4C9A-BB58-CF30E0E6D8BDQ33944226-8C6E4DF9-98E5-4AAC-9BC6-4D88A33E07DBQ34391064-B1F93289-EAFE-488F-807E-66B15BCE9288Q34786812-B743F05B-D327-4787-9DE7-095CF515F363Q35621833-297AF28D-707A-4D22-838B-1B71B91EFACDQ36243568-55CDDFD9-48C2-4FFD-B153-0BF745E720EBQ36373006-4EB41AD5-56CA-4B3B-B2B9-65104E6D3589Q37181858-11340546-D3CB-4860-BF04-E9A336BCF630Q37221349-9F369F47-C214-459D-9A58-D3F1B27F28B0Q37785420-80D5253B-804A-49EF-B0E6-63E86137DD66Q38310102-2C582A3B-D274-429B-A81E-72E100F71A31Q42148662-10B69438-7512-4BB5-948F-E1E782CB5124Q48161919-EF80C961-F246-406B-8187-7C559B2991DDQ48323370-9FDD8DB3-C993-4D55-A86D-383118AE5AC0
P2860
An endogenous serine/threonine protein phosphatase inhibitor, G-substrate, reduces vulnerability in models of Parkinson's disease.
description
2007 nî lūn-bûn
@nan
2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
An endogenous serine/threonine ...... models of Parkinson's disease.
@ast
An endogenous serine/threonine ...... models of Parkinson's disease.
@en
type
label
An endogenous serine/threonine ...... models of Parkinson's disease.
@ast
An endogenous serine/threonine ...... models of Parkinson's disease.
@en
prefLabel
An endogenous serine/threonine ...... models of Parkinson's disease.
@ast
An endogenous serine/threonine ...... models of Parkinson's disease.
@en
P2093
P2860
P1476
An endogenous serine/threonine ...... models of Parkinson's disease.
@en
P2093
Chee Yeun Chung
James B Koprich
Ole Isacson
Shogo Endo
P2860
P304
P356
10.1523/JNEUROSCI.1972-07.2007
P407
P577
2007-08-01T00:00:00Z